Samacheer Class 12 Bio Zoology - Applications of Biotechnology

Two primers are required in each cycle of PCR: a forward primer and a reverse primer. Primers are short synthetic oligonucleotide sequences, typically 18-25 nucleotides long, that are complementary to the flanking sequences at the ends of the target DNA region to be amplified. The primers serve the critical role of providing a free 3'-OH group that acts as the starting point for DNA synthesis, allowing DNA polymerase to recognize where to begin synthesis and ensuring that amplification is specific to the desired target sequence. DNA polymerase, specifically the heat-stable Taq polymerase, catalyzes the extension of primers by adding deoxynucleotide triphosphates (dNTPs) in the 5' to 3' direction, synthesizing new complementary DNA strands. The heat-stable nature of Taq polymerase is essential because it allows the enzyme to remain active through repeated cycles of heating and cooling without denaturation. Taq polymerase is derived from the thermophilic bacterium Thermus aquaticus, which naturally inhabits hot springs and has evolved to maintain enzymatic activity at high temperatures. This source organism is crucial to the success of PCR as a technique, as the enzyme's thermostability enables the automated thermal cycling that is fundamental to the polymerase chain reaction process.

PCR amplification of a gene sample of interest is carried out through a series of carefully controlled steps. The reaction mixture is prepared by combining template DNA containing the target sequence, two specific primers (forward and reverse) that flank the region of interest, deoxynucleotide triphosphates (dNTPs) providing the building blocks for DNA synthesis, a buffer solution maintaining optimal pH, magnesium ions (Mg2+) as cofactors for DNA polymerase activity, and heat-stable DNA polymerase, typically Taq polymerase from Thermus aquaticus. The amplification process involves repeated thermal cycling with three distinct temperature phases. During denaturation at approximately 94-95°C, the double-stranded DNA template separates into single strands. In the annealing phase at 50-65°C (the exact temperature depends on primer design), the primers bind specifically to their complementary sequences on the template strands. During the extension phase at approximately 72°C, Taq polymerase synthesizes new DNA strands by extending from the 3'-OH end of the primers, incorporating dNTPs in the 5' to 3' direction. This three-step cycle is repeated 25-35 times, with each cycle doubling the amount of target DNA, resulting in exponential amplification producing approximately 2^n copies of the target sequence where n is the number of cycles. A thermal cycler instrument automates the temperature changes and timing of each cycle, ensuring precise and rapid cycling. After amplification is complete, the PCR product is typically analyzed by gel electrophoresis to visualize the amplified DNA fragment and confirm successful amplification of the correct target sequence.

Genetically engineered insulin, also known as recombinant insulin, is human insulin produced using recombinant DNA technology and biotechnology methods. The human insulin gene, or alternatively the separate genes encoding the A and B chains of insulin or the proinsulin precursor, is isolated and inserted into expression vectors. These vectors are introduced into microorganisms such as Escherichia coli or yeast cells, which then serve as biological factories to express the human insulin gene. The microorganisms synthesize the insulin protein or its precursor, which is then harvested from the culture medium or cells and subjected to purification and processing steps. If proinsulin is produced, it is enzymatically cleaved to generate mature insulin with the correct A and B chains. The resulting recombinant insulin is chemically and functionally identical to naturally occurring human insulin produced by the pancreas. This identity to human insulin is a major advantage over previously used animal insulins derived from bovine or porcine pancreases, as it significantly reduces the risk of immune reactions and allergic responses in diabetic patients. Recombinant insulin products such as Humulin have revolutionized diabetes treatment by providing a reliable, consistent, and abundant supply of pure human insulin that is safer and more effective than animal-derived insulin preparations.

Rosie is a transgenic cow that differs fundamentally from a normal cow in that she has been genetically engineered to express a human gene in her mammary glands. Specifically, Rosie carries a human gene encoding alpha-lactalbumin, a human milk protein, which has been stably integrated into her genome. This human gene is placed under the control of a mammary-specific promoter, ensuring that the gene is expressed exclusively or predominantly in the mammary tissue during lactation. As a result of this genetic modification, Rosie's milk contains the human alpha-lactalbumin protein in addition to the normal bovine milk proteins. Unlike normal cows, whose milk contains only bovine proteins, Rosie's milk is enriched with a human protein that improves its nutritional composition and therapeutic properties. This transgenic approach has practical applications in producing milk with enhanced nutritional value for infant formula or in using the milk as a source for therapeutic protein production. Rosie represents an important example of how transgenic animals can be engineered to produce valuable human proteins in their milk, a process known as pharming, which provides an efficient and cost-effective method for producing human proteins on a large scale.

Before the advent of recombinant DNA technology, insulin was obtained exclusively through extraction and purification from animal pancreases, primarily from cattle (bovine) and pigs (porcine) slaughtered for meat production. The pancreatic tissue was processed to isolate and purify insulin, which was then used therapeutically for diabetic patients. However, this method of insulin production encountered numerous significant problems. The supply of insulin was inherently limited because it depended on the availability of animal pancreases from slaughterhouses, making it difficult to meet the growing global demand for insulin. The supply was also variable and inconsistent from batch to batch due to variations in animal sources and extraction efficiency. Animal insulin differed slightly in amino acid sequence from human insulin, particularly in a few positions, which caused immune and allergic reactions in some patients, including insulin resistance and lipodystrophy at injection sites. The risk of contamination with other pancreatic proteins and potentially harmful agents was present, requiring extensive purification procedures. The extraction, purification, and processing of animal insulin was expensive and labor-intensive, making insulin therapy costly and inaccessible to many patients. Batch inconsistency in purity and potency created challenges in standardizing treatment and dosing. These limitations of animal-derived insulin highlighted the need for an alternative source, which was ultimately provided by recombinant DNA technology enabling the production of pure, consistent, human insulin in unlimited quantities.

ELISA (Enzyme-Linked Immunosorbent Assay) is a technique based on antigen-antibody reactions and is primarily designed to detect and quantify proteins or antibodies in a sample. In principle, ELISA could potentially be used to measure enzyme levels in phenylketonuria (PKU) by detecting phenylalanine hydroxylase protein if specific antibodies against this enzyme are available, thereby providing indirect information about enzyme deficiency. However, ELISA cannot be used for definitive molecular diagnosis of genetic disorders like PKU because it does not detect DNA mutations, which are the underlying genetic cause of the disease. Molecular diagnosis of PKU requires different approaches: biochemical testing such as newborn screening that measures elevated levels of phenylalanine in blood or urine, which is the primary diagnostic indicator of PKU, or DNA-based molecular methods including PCR amplification of the phenylalanine hydroxylase gene followed by DNA sequencing to identify the specific causative mutations. These molecular techniques directly identify the genetic defects responsible for PKU, providing definitive diagnosis and enabling genetic counseling and family screening. Therefore, while ELISA might provide supplementary information about enzyme levels, it is of limited utility for the molecular diagnosis of genetic disorders and cannot replace biochemical or DNA-based diagnostic methods that are necessary for accurate identification of PKU and other genetic diseases.

Gene therapy is generally considered the preferable option when it is safe and technically feasible because it addresses the root cause of genetic defects by providing a functional normal gene that integrates into the patient's genome and is expressed in the patient's own cells. Once successfully established, gene therapy can provide long-term or potentially permanent production of the missing or defective protein by the patient's own cells, offering a durable solution to the genetic problem. In contrast, enzyme replacement therapy (ERT) provides only temporary relief of symptoms because the exogenous enzyme is gradually degraded and must be repeatedly administered to maintain therapeutic levels. ERT requires frequent and lifelong administrations, making it burdensome for patients and expensive for healthcare systems. Additionally, repeated administration of foreign proteins in ERT can provoke immune responses and allergic reactions, reducing efficacy over time. However, gene therapy carries its own significant risks and limitations that must be considered. These include potential safety issues related to the viral or non-viral vectors used to deliver the gene, the risk of insertional mutagenesis where the integrated gene disrupts normal genes and causes adverse effects, and possible immune reactions against the vector or the newly expressed protein. Technical challenges in achieving efficient gene delivery to target tissues and ensuring appropriate regulation of gene expression also exist. Therefore, the choice between gene therapy and ERT depends on multiple factors including the specific disease being treated, the availability and safety profile of gene therapy approaches, the severity and progression of the disease, the feasibility of repeated ERT administrations, and a careful risk-benefit analysis for each individual patient. In some cases, ERT may be preferable as a short-term or interim treatment while safer gene therapy methods are being developed, or when gene therapy is not yet available or proven safe for that particular genetic disorder.

Transgenic animals are organisms that have had foreign DNA stably integrated into their genome through genetic engineering techniques, and which express the transgene (foreign gene) in their somatic cells and often in their germ cells as well, allowing the trait to be inherited by offspring. The foreign DNA becomes a permanent part of the animal's genetic makeup and is replicated along with the host genome during cell division. Transgenic animals are created using various methods including microinjection of DNA into the pronucleus of fertilized eggs, electroporation, or use of viral vectors, and have numerous important applications in research, medicine, and agriculture. Transgenic mice are extensively used in biomedical research to model human genetic diseases, study gene function, and test potential therapeutic interventions. Transgenic goats have been engineered to produce human antithrombin, a blood-clotting protein, in their milk, which is then harvested and purified for therapeutic use in patients with antithrombin deficiency. Transgenic salmon, such as AquAdvantage salmon, carry a growth hormone gene that enables them to grow faster than wild-type salmon, providing agricultural benefits through increased food production. Transgenic cows, including Rosie, have been engineered to produce human milk proteins such as alpha-lactalbumin in their milk, improving nutritional properties for infant formula or enabling production of therapeutic proteins. Transgenic pigs have been engineered with modifications to reduce immune rejection, making them candidates for xenotransplantation to provide organs and tissues for human transplantation. These diverse examples demonstrate the wide-ranging applications of transgenic animal technology in advancing medical treatment, improving agricultural productivity, and facilitating scientific research.

Yes, ELISA will be helpful for diagnosing HIV infection, but with important limitations and timing considerations. ELISA detects anti-HIV antibodies produced by the immune system in response to HIV infection. These antibodies typically appear within two to twelve weeks after exposure, a period known as the window period. During this early window period, an infected person may test negative on ELISA despite being infected and capable of transmitting the virus, which is a critical limitation. After the window period has passed, ELISA becomes highly reliable and sensitive for detecting HIV antibodies. However, for detection during the window period, alternative or complementary tests are necessary. Fourth-generation combination antigen/antibody tests can detect both HIV antibodies and p24 antigen (a viral protein), reducing the window period to approximately eighteen to forty-five days. Nucleic acid testing (NAT) or PCR for viral RNA can detect HIV even earlier, within one to four weeks of infection. Therefore, the recommended approach is to perform an initial ELISA test, and if negative but clinical suspicion remains high, repeat the test after the window period or use combination antigen/antibody tests or NAT for earlier and more reliable diagnosis. This multi-test strategy ensures that HIV infection is not missed due to the window period limitation of standard ELISA.

ADA deficiency, a form of severe combined immunodeficiency (SCID), can be corrected through three main therapeutic approaches. The first approach is enzyme replacement therapy, in which purified adenosine deaminase (ADA) enzyme is supplied to the patient periodically, either as the native enzyme or as a modified form (such as pegylated ADA), to compensate for the deficient enzyme and prevent accumulation of toxic metabolites that damage lymphocytes. The second approach is hematopoietic stem cell or bone marrow transplantation from a matched donor, which replaces the patient's defective hematopoietic cells with healthy donor cells that produce functional ADA enzyme, thereby restoring immune function. This approach can provide long-term correction but requires a suitable matched donor and carries risks of graft rejection and graft-versus-host disease. The third and most promising approach is gene therapy using ex vivo methodology. In this method, hematopoietic stem cells or lymphocytes are isolated from the patient's bone marrow or blood, transduced in the laboratory with a recombinant vector (such as a retroviral or lentiviral vector) carrying a functional ADA complementary DNA (cDNA), cultured to expand the corrected cells, and then reinfused into the patient. Once reinfused, these genetically corrected cells produce functional ADA enzyme and can self-renew, providing long-term restoration of immune function. Gene therapy offers the advantage of using the patient's own cells, avoiding the need for a donor match, and potentially providing permanent correction of the genetic defect.

DNA vaccines are a novel class of vaccines composed of plasmid DNA constructs that encode antigenic proteins of a pathogen. When administered to a patient, typically through intramuscular injection, the plasmid DNA is taken up by host cells, including muscle cells and antigen-presenting cells. Once inside the host cells, the plasmid DNA is transcribed and translated, resulting in the in vivo expression of the pathogenic antigen within the patient's own cells. The expressed antigen is then processed and presented to the immune system via major histocompatibility complex (MHC) pathways, both MHC class I and class II, which stimulates both cellular immunity (cytotoxic T lymphocytes) and humoral immunity (antibody production). This dual immune response is a significant advantage of DNA vaccines. Additional advantages include excellent stability of plasmid DNA, ease and low cost of production compared to conventional vaccines, rapid development timelines, and the ability to induce broad and long-lasting immune responses. DNA vaccines have been developed or are in clinical trials for various infectious diseases and some cancers, representing a promising frontier in vaccine technology.

Somatic cell gene therapy and germline gene therapy differ fundamentally in their target cells and the heritability of genetic changes. Somatic cell gene therapy involves the introduction, replacement, or correction of defective genes specifically in the somatic (body) cells of an affected individual, such as liver cells, muscle cells, blood cells, or neurons. The genetic modifications made in somatic cells affect only that individual and are not passed on to offspring because they do not alter the genetic material in reproductive cells (gametes). Therefore, somatic cell gene therapy produces non-heritable changes that benefit only the treated patient. In contrast, germline gene therapy involves modification of genes in germline cells, which include gametes (sperm and egg cells) or cells in early embryos before differentiation. Because germline cells are the precursors to all cells in an organism and are passed to the next generation, any genetic modifications made in germline cells are heritable and will be transmitted to offspring and subsequent generations. Consequently, germline gene therapy produces permanent, heritable changes in the genetic makeup of a family line. Due to these fundamental differences in heritability and scope, somatic cell gene therapy is currently the only form of gene therapy permitted in clinical practice in most countries, while germline gene therapy remains ethically controversial and is not permitted in humans in most jurisdictions due to concerns about unintended consequences, long-term effects, and ethical implications for future generations.

Stem cells are undifferentiated cells that possess two defining characteristics: the capacity for self-renewal through cell division and the potential to differentiate into one or more specialized cell types. Stem cells are classified based on their potency, which refers to the range of cell types they can differentiate into. Totipotent stem cells, such as the zygote and early blastomeres, can differentiate into all cell types including extraembryonic tissues. Pluripotent stem cells, such as embryonic stem cells, can differentiate into any cell type of the body but not extraembryonic tissues. Multipotent stem cells, such as hematopoietic stem cells and mesenchymal stem cells, can differentiate into a limited range of specialized cell types within a particular tissue or organ system. In the field of medicine, stem cells have transformative applications. Hematopoietic stem cell transplantation is used to treat blood cancers such as leukemia and lymphoma, as well as other blood disorders. Stem cells are employed in regenerative medicine to repair or replace damaged tissues and organs, with potential applications in treating spinal cord injuries, heart disease, and neurodegenerative diseases such as Parkinson's disease. Stem cells are valuable for disease modeling, allowing researchers to create in vitro models of genetic and acquired diseases to understand disease mechanisms. They are also used in drug testing and toxicity screening to evaluate the safety and efficacy of new pharmaceutical compounds. Additionally, stem cell-based therapies show promise for treating conditions such as diabetes, where stem cells could be differentiated into insulin-producing beta cells to restore glucose homeostasis. The regenerative and therapeutic potential of stem cells makes them a cornerstone of modern medicine and regenerative biology.

i) Gene therapy is defined as the introduction, replacement, or correction of defective or mutated genes into the cells of an affected individual to treat, prevent, or alleviate the symptoms of a genetic disease. The therapeutic goal is to restore normal gene function and thereby restore normal cellular and physiological function. ii) The hereditary disease for which the first clinical gene therapy was successfully used is adenosine deaminase (ADA) deficiency, also known as ADA-severe combined immunodeficiency (ADA-SCID). This is a rare genetic disorder in which mutations in the ADA gene result in deficiency of the enzyme adenosine deaminase, leading to accumulation of toxic metabolites that are particularly damaging to lymphocytes, resulting in severe immunodeficiency. iii) The steps involved in gene therapy to treat ADA deficiency are as follows. First, the functional ADA gene is isolated and cloned into an appropriate expression vector, typically a retroviral or lentiviral vector that can efficiently transduce human cells. Second, the recombinant vector carrying the functional ADA gene is used to transduce patient-derived lymphoid cells or hematopoietic stem cells in vitro (ex vivo gene therapy). Third, the transduced cells are selected and expanded in culture to ensure that a sufficient population of genetically corrected cells is obtained. Fourth, the expanded population of corrected cells is reinfused into the patient through intravenous infusion. Fifth, the reinfused cells home to lymphoid tissues and bone marrow, where they establish themselves and produce functional ADA enzyme, thereby restoring immune function. Finally, the patient's immune function is monitored over time through measurement of lymphocyte counts, T cell function, and clinical improvement in immune status. This pioneering application of gene therapy demonstrated the feasibility of treating genetic diseases through genetic modification of patient cells.

PCR (polymerase chain reaction) is an invaluable molecular tool for the early diagnosis of infectious diseases because it enables rapid and highly sensitive detection of pathogen-specific nucleic acid sequences from clinical samples. The principle underlying PCR-based diagnosis is that even when the pathogen load in a patient's sample is extremely low, PCR can amplify specific DNA or RNA sequences of the pathogen exponentially through repeated cycles of denaturation, primer annealing, and DNA synthesis, producing millions of copies of the target sequence that can be easily detected. This high sensitivity allows detection of pathogens at very early stages of infection, often before symptoms appear or before conventional diagnostic methods such as culture or serology become positive. Reverse transcription PCR (RT-PCR) extends the utility of PCR to RNA viruses such as influenza, coronavirus, and HIV by first converting viral RNA to complementary DNA (cDNA) before amplification. Real-time PCR or quantitative PCR (qPCR) further enhances diagnostic capability by monitoring the accumulation of PCR products in real-time during the amplification process, allowing not only detection but also quantification of pathogen load, which is valuable for assessing disease severity and monitoring treatment response. The speed of PCR-based diagnosis is another major advantage; results can be obtained within hours compared to days or weeks required for culture-based methods. Additionally, PCR can be designed to detect multiple pathogens simultaneously (multiplex PCR) and can distinguish between different strains or variants of a pathogen. These characteristics make PCR an essential tool in clinical microbiology laboratories for early, accurate, and rapid diagnosis of infectious diseases, enabling prompt initiation of appropriate treatment and infection control measures.

Recombinant vaccines are vaccines produced using recombinant DNA technology and genetic engineering to express specific antigenic proteins of a pathogen without the need to use whole pathogenic organisms. This approach eliminates the risks associated with conventional vaccines that use attenuated or inactivated whole pathogens, such as the possibility of reversion to virulence or incomplete inactivation. Recombinant vaccines can be classified into several types based on their composition and production method. Recombinant subunit protein vaccines consist of purified antigenic proteins produced by expressing pathogen genes in host cells such as bacteria, yeast, or insect cells, and then purifying the expressed proteins for use as the vaccine antigen. Virus-like particle (VLP) vaccines are composed of self-assembling protein structures that mimic the morphology of viruses but lack the viral genome, providing high immunogenicity without infectivity; examples include papillomavirus and hepatitis B virus VLP vaccines. Viral-vectored vaccines use a non-pathogenic or attenuated virus as a vector to deliver and express pathogenic antigens within host cells, thereby stimulating both cellular and humoral immune responses. DNA vaccines consist of plasmid DNA encoding pathogenic antigens that are taken up by host cells and expressed in vivo, stimulating immune responses. Recombinant live attenuated vaccines are live pathogens that have been genetically modified to reduce virulence while maintaining immunogenicity. Each type of recombinant vaccine offers distinct advantages in terms of safety, immunogenicity, ease of production, and stability, and the choice of vaccine type depends on the specific pathogen and the desired immune response.

The cloning of Dolly the sheep in 1996 was a major scientific breakthrough because it definitively demonstrated that a fully differentiated adult somatic cell nucleus retains all the genetic information necessary to direct the development of an entire organism. Prior to Dolly's creation, the prevailing scientific view was that differentiation was largely irreversible and that adult somatic cell nuclei had lost the ability to support full development. Dolly was produced through somatic cell nuclear transfer (SCNT), in which the nucleus from an adult mammary gland cell of a donor sheep was transferred into an enucleated egg cell from another sheep, and the reconstructed embryo was then implanted into a surrogate mother. The successful birth of Dolly proved that the genetic material in the adult somatic cell nucleus could be reprogrammed by the cytoplasm of the egg cell to a totipotent state, capable of directing the development of all cell types and tissues in the body. This demonstrated the principle of genomic equivalence, which states that all cells in an organism contain the same genetic information despite their different phenotypes and functions. The reprogramming of the differentiated nucleus to totipotency by the egg cytoplasm revealed that differentiation involves reversible changes in gene expression rather than permanent loss of genetic material. Dolly's creation opened new frontiers in reproductive biology, regenerative medicine, and biotechnology, enabling the possibility of producing cloned animals for research, agriculture, and potentially therapeutic purposes. The breakthrough also raised important questions about the nature of development, cellular differentiation, and the ethical implications of cloning technology.

Cloning technology offers several significant advantages but also presents substantial disadvantages and challenges. The advantages of cloning include the ability to reproduce animals that possess desirable traits, such as high milk production in dairy cattle or disease resistance in livestock, thereby accelerating selective breeding programs. Cloning can be used for conservation of endangered species by creating genetic copies of individuals, potentially helping to preserve species on the brink of extinction. Cloning produces genetically identical animals that serve as valuable research models, eliminating genetic variability and allowing more precise study of gene function and disease mechanisms. Cloning technology enables the production of transgenic animals carrying foreign genes, which can be used to produce therapeutic proteins such as insulin, growth hormone, and clotting factors in their milk or blood. Therapeutic cloning, which involves creating cloned embryos for the purpose of harvesting stem cells rather than producing a cloned animal, offers potential for regenerative medicine and treatment of degenerative diseases. However, cloning has significant disadvantages. The efficiency of cloning is extremely low, with success rates typically ranging from one to four percent, meaning that the vast majority of cloning attempts fail, resulting in high wastage of eggs and surrogates. Cloned animals frequently exhibit developmental abnormalities and birth defects, including large offspring syndrome, immune deficiencies, organ malformations, and developmental delays. Cloned animals often show reduced genetic diversity and may inherit mitochondrial DNA from the egg donor, potentially causing genetic imbalances. Cloned animals frequently experience health problems and shortened lifespans compared to naturally conceived animals, with increased susceptibility to infections and age-related diseases. Ethical concerns surround cloning, particularly regarding animal welfare, the potential for human cloning, and the implications of creating genetically identical individuals. The technical complexity and high cost of cloning procedures make them economically unfeasible for most applications. These disadvantages have limited the practical application of cloning technology and continue to fuel scientific and ethical debate about its appropriate use.